The gene transfer efficiency of human hematopoietic stem cells is still inadequate for efficient gene therapy of most disorders. To overcome this problem, a selectable retroviral vector system for gene therapy has been developed for gene therapy of Gaucher disease. We constructed a bicistronic retroviral vector containing the human glucocerebrosidase (GC) cDNA and the human small cell surface antigen CD24 (243 bp). Expression of both cDNAs was controlled by the long terminal repeat enhancer/promoter of the Molony murine leukemia virus. The CD24 selectable marker was placed downstream of the GC cDNA and its translation was enhanced by inclusion of the long 5' untranslated region of encephalomyocarditis virus internal ribosomal entry site. Virus-producing GP+envAM12 cells were created by multiple supernatant transductions to create vector producer cells. The vector LGEC has a high titer and can drive expression of GC and the cell surface antigen CD24 simultaneously in transduced NIH 3T3 cells and Gaucher skin fibroblasts. These transduced cells have been successfully separated from untransduced cells by fluorescence-activated cell sorting, based on cell surface expression of CD24. Transduced and sorted NIH 3T3 cells showed higher GC enzyme activity than the unsorted population, demonstrating coordinated expression of both genes. Fibroblasts from Gaucher patients were transduced and sorted for CD24 expression, and GC enzyme activity was measured. The transduced sorted Gaucher fibroblasts had a marked increase in enzyme activity (149%) compared with virgin Gaucher fibroblasts (17% of normal GC enzyme activity). Efficient transduction of CD34+ hematopoietic progenitors (20-40%) was accomplished and fluorescence-activated cell sorted CD24+-expressing progenitors generated colonies, all of which (100%) were vector positive. The sorted, CD24-expressing progenitors generated erythroid burst-forming units, colony-forming units (CFU)-granulocyte, CFU-macrophage, CFU-granulocyte/macrophage, and CFU-mix hematopoietic colonies, demonstrating their ability to differentiate into these myeloid lineages in vitro. The transduced, sorted progenitors raised the GC enzyme levels in their progeny cells manyfold compared with untransduced CD34+ progenitors. Collectively, this demonstrates the development of high titer, selectable bicistronic vectors that allow isolation of transduced hematopoietic progenitors and cells that have been metabolically corrected.
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Gaucher disease is an autosomal recessive lysosomal storage disorder caused by a deficiency of the enzyme glucocerebrosidase (GC) (1) . The disease is characterized by accumulation of glucocerebroside in macrophages and macrophage-derived cells in various tissues (2, 3) . Effective enzyme replacement therapy has now been developed for Gaucher disease (4, 5) ,
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but this is not a permanent cure for the disease. Allogeneic bone marrow transplantation has been successful for the treatment of Gaucher disease (6, 7) , but the high level of mortality and morbidity that can be associated with this procedure is problematic. This has prompted several investigators to develop gene therapy for Gaucher disease by gene transfer into hematopoietic stem cells (8) . The human GC gene has been transduced into murine bone marrow stem cells and elevated levels of GC enzyme activity have been observed in mouse macrophages of long-term reconstituted mice (9) (10) (11) . The GC gene has also been transduced into hematopoietic progenitor cells from bone marrow (12) (13) (14) and peripheral blood (15) of Gaucher patients, and the enzyme deficiency has been corrected in their progeny cells. Furthermore, primitive human hematopoietic cells that can repopulate immunocompromised BNX mice have been transduced with GC vectors (16) . Gene therapy of hematopoietic stem cells (HSCs) has been under investigation as a potential treatment for many genetic disorders of the hematopoietic system (17, 18) . While retroviral transduction of murine HSCs is quite efficient, human HSCs have proven to be more resistant to retroviral transduction. Attempts have been made to increase the efficiency of retroviral transduction into human hematopoietic stem and progenitor cells by various transduction methods including the use of purified growth factors (19, 20) , stromal cells (16, 21) , a combination of stroma and growth factors (14, 15) , alternative sources of hematopoietic stem and progenitor cells (22) , and purification of CD34+ cells (23) . Many of these approaches have improved transduction efficiency into clonogenic progenitor cells, but it has proven more difficult to transduce repopulating HSCs from monkeys efficiently (24) (25) (26) , and similar difficulties are expected for human stem cells. Another approach to address this problem is to develop a method to select the transduced cells by using cell surface antigen genes in the vectors (27) (28) (29) (30) . Recently, the multidrug resistance gene (MDR1) has been used for this purpose (31) (32) (33) . The MDR1 gene encodes the 170-kDa plasma membrane protein (31) . The transduced cells overexpressing this protein can be sorted by fluorescence-activated cell sorting (FACS) (34) and by cytotoxic agents like taxol in vivo (32) . Unfortunately, the MDR1 gene is large and when it is added to a retroviral vector containing a therapeutic gene the double gene vector tends to have a low titer, which compromises its use for HSCs as targets (35) . In contrast, the human hematopoietic cell surface antigen CD24 is small and its cDNA is only 243 bp (36 Proc. Natl. Acad. Sci. USA 92 (1995) been generated and used to transduce murine HSCs (29 (9, 13) . Alternatively, the 1.6-kbp GC cDNA (10, 12) was used, creating a slightly shorter (but otherwise identical) LGEC vector.
Cells. The transient ecotropic virus-producing BOCS 23 cells (38) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Biofluids, Rockville, MD), 10% heatinactivated fetal bovine serum (HyClone), 2 mM glutamine, penicillin (100 units/ml), and streptomycin (100 jig/ml) (Biofluids). The amphotropic virus-producing GP+envAM12 cells (39) , the targeted NIH 3T3 cells, and human skin fibroblasts were cultured as described (9, 11, 13) .
High-titer amphotropic virus-producing GP+envAM12 cells were created by multiple infection with ecotropic virus supernatants from transient ecotropic virus-producing BOSC 23 cells as described (13) . The transduction was repeated 17 times and a high-titer clone was identified after screening 20 colonies (9, 13) . Viral titers were expressed as copies per transduced cell per ml of vector supernatant. Detection of helper virus was performed by a marker rescue assay (40) .
Transduction of Target Cells. NIH 3T3 cells were transduced once and infected with 1 ml of viral supernatants and 9 ml of standard medium containing Polybrene (8 ,ug/ml).
Gaucher skin fibroblasts were infected six times for 6 consecutive days with 5 ml of viral supernatants and 10 ml of standard medium containing protamine sulfate (4 ,tg/ml) (Elkins-Sinn, Cherry Hill, NJ). Both infected NIH 3T3 cells and Gaucher skin fibroblasts were sorted from untransduced cells based on cell surface expression of CD24 by FACS. CD34+ human hematopoietic progenitors from bone marrow were isolated with a Ceparate column (CellPro, Bothell, WA) and transduced by viral supernatant, protamine sulfate, interleukin (IL)-3, IL-6, and stem cell factor (SCF) on top of stromal cells as described (15) . Human hematopoietic progenitor assays were done in methylcellulose (Stem Cell Technologies, Vancouver, Canada) using granulocyte/macrophage colonystimulating factor (GM-CSF) (20 ng/ml) only or GM-CSF and IL-3 (10 ng/ml), SCF (50 ng/ml), and erythropoietin (3 units/ml).
FACS Analysis. This procedure has been described in detail (29) . Briefly, infected cells were lifted out of the culture dishes using phosphate-buffered saline with 2 mM EDTA and resuspended in Hanks' balanced salt solution (GIBCO/BRL) containing 2% fetal calf serum and 0.1% sodium azide (Sigma).
The cells (1 X 106) were labeled with tetramolecular complexes of monoclonal antibodies mixed with anti-CD24 antibody 32D12, anti-R-phycoerythin antibody ID3, and F(ab')2 fragments of the anti-IgG antibody p946 at a 1:2:3 ratio. Sequentially, cells were washed twice with HFN and stained with R-phycoerythin. Cells were analyzed and sorted with a FACStar' (Becton Dickinson).
GC Enzyme Activity Assay and DNA Analysis. Standard techniques were used to measure GC enzyme activity and to perform Southern blot analysis and semiquantitative PCR (13, 26) .
RESULTS
The LGEC Vector-Producing Cells. As shown in Fig. 1, LGEC is a murine retrovirus-based vector that contains both the human GC cDNA and the human small cell surface antigen CD24 cDNA. Expression of both cDNAs is controlled by the LTR enhancer/promoter of the MoMLV by placing the CD24 selectable marker gene downstream of the GC cDNA and the IRES from EMCV. A high-titer-GP+envAMl2/LGEC clone (clone 5) was selected initially by screening for GC enzyme production, expression of CD24 antigen by flow cytometry, and copy number of the provirus by Southern blotting. The titer was determined by Southern blot analysis of transduced 3T3 cells to estimate proviral copy number in the target cells. Clone 5 was found to have at least 10 proviral copies in comparison with copy number control samples, its GC enzyme activity was 3.9-fold higher than untransduced GP+envAM12 cells, and expression of CD24 on the surface of the GP+envAM12/LGEC producer clone 5 was confirmed by FACS (data not shown). These producer cells produce high titer (0.3-1 copy per cell per ml on 3T3 cells) as shown in Fig.  2 . This titer is similar to high-titer vector clones produced in our laboratory that have been titered side by side by Southern blot analysis of target cells, as done here, and a limiting dilution colony-forming assay (11) .
Selection of Transduced 3T3 Cells. CD24 expression was detectable in 60% of the transduced 3T3 cells by FACS analysis after passaging the cells several times. They were successfully selected into the top 20% fraction (Ml) and the next 40% fraction (M2) based on the expression level of the CD24 cell surface antigen (Fig. 2A) . GC enzyme activities of the top 20% fraction and the next 40% fraction were 484.9 ± 33.8 nmol per hr per mg of protein and 296.3 + 15.6 nmol per hr per mg of protein, respectively, which represented 1.8-and 1.1-fold more than the transduced unsorted population (Fig. 2B) . To confirm that this procedure selects cells that are actually transduced, Southern blot analysis was performed with genomic DNAs from each cell fraction. Fig. 2C shows that the transduced NIH 3T3 cells in the top 20%-expressing fraction contain more proviral copies than the other cell fractions. There is a good correlation between proviral copy number and CD24 expression level in these cell populations. Therefore, these data LD2-[ demonstrate simultaneous production of GC enzyme and the cell surface antigen CD24.
Selection and Correction of Enzyme Deficiency in Gaucher Skin Fibroblasts. Skin fibroblasts from a Gaucher patient were transduced six times with viral supernatants. FACS analysis demonstrated that transduced fibroblasts had high levels of surface CD24 antigen, while uninfected Gaucher fibroblasts had little or no expression of CD24. Approximately 40% of Gaucher fibroblasts expressed high levels of surface antigen CD24 after transduction. The positive fraction, which represented 40% of the population, was sorted to isolate transduced from nontransduced cells (Fig. 3A) . While the GC enzyme activity of the transduced, unsorted Gaucher fibroblasts was increased to 182.9 + 1.3 nmol per hr per mg of protein (42% of normal control), the sorted Gaucher fibroblasts showed an increase to 648.9 -5.7 nmol per hr per mg, or 1.5-fold higher than that of normal skin fibroblasts (Fig. 3B) . To verify that the Genomic DNAs (100 ng) from normal (lane N), Gaucher (lane G), transduced unsorted Gaucher (lane GU), and transduced sorted Gaucher (lane GS) skin fibroblasts were PCR amplified and compared with serial dilutions (500-10 ng) of genomic DNA from a LG viral-producing cell line containing one proviral copy per cell. PCR products were run on an agarose gel and Southern blot analysis was performed with a GC probe. The signals were quantified by a scanner and were linear from 500 ng to 10 ng of the copy number control sample shown (the GS and the GU signals fall within the linear range). The GS signal was many times stronger than the GU signal as expected. The unidentified middle band in the GU and GS lanes is sometimes seen with the primers, but only in cells that are vector positive. increase in GC enzyme activity was due to increased proviral copy number in the sorted fibroblast fraction, semiquantitative PCR analysis was performed. The specific GC signal (295 bp) of sorted fibroblasts was much stronger than the signal in the unsorted cells (Fig. 3C ). These experiments demonstrate metabolic correction of the enzyme deficiency using the LGEC vector and that cell surface selection can be used to isolate transduced cells from Gaucher patients. Sorting of LGEC Transduced CD34+ Hematopoietic Progenitors. CD34+ human hematopoietic progenitor cells were transduced with a LGEC vector containing a shorter form (1.6 kb) of the GC cDNA (10, 12) than the cDNA used above (the shorter cDNA results in higher enzyme activity per copy number of vector after gene transfer; unpublished studies). The transduced cells were sorted by FACS (Fig. 4A) and the unsorted and sorted fractions were plated into methylcellulose for assays of hematopoietic colonies. The colonies were picked and analyzed individually for the presence of the vector by PCR (13) . Many colonies were pooled together for GC enzyme activity measurement. Transduction efficiency of total hematopoietic colonies was 20-40%, compared with 33-65% for the LG vector (13, 15) , and all the colonies from the CD24+ fraction were vector positive by PCR ( Table 1 ). The enzyme activities of the transduced progenitor-derived colonies were 2-fold (unsorted) and 6-fold (sorted) compared with virgin CD34+ cells (Fig. 4B) . In contrast, the transduced CD24-colonies resulted in colonies with normal GC enzyme activity. Various hematopoietic colony types generated from progenitors that were or were not expressing the CD24 molecule were compared in order to determine whether CD24 expression alters in vitro myeloid differentiation of human hematopoietic progenitors. The percentage of the different colony types from LG transduced (not expressing CD24) and LGEC transduced and sorted progenitors was as follows: erythroid burst-forming units, 17.5% vs. 26.7%; colony-forming units (CFU)-G, 14.1% vs. 6.7%; CFU-M, 12.2% vs. 6.7%; CFU-GM, 49.1% vs. 50%; CFU-mix, 7.0% vs. 10.0%. Sorted CD24-and CD24+ progenitors generated almost identical ratios of the above colony Several groups have reported coordinated expression of two genes from a single mRNA in a bicistronic vector using an IRES element (33, 37, 41) . Expression of a coding region in the downstream position was reported as 25-100% of the expression levels when the same coding region was located in the upstream position. The expression level depends on the cDNA itself and the number of stop codons identified by the translation machinery during translation (37). We did not place CD24 in the 5' position within the vector to compare expression levels with that of the 3' position, but the CD24 cDNA in the 3' position was easily expressed at high enough levels by the IRES to allow selection of the transduced cells by FACS.
Many selectable marker genes have been used in retroviral vector systems for selection of transduced cells-for example, the resistance genes for neomycin (42, 43) and hygromycin (44) . Although these are used widely in many gene transfer experiments, these systems have many disadvantages, including exposure to nonspecific drug toxicity of target cells, long duration of the selection procedure, and difficulties in quantitating expression levels for the selection of transduced cells. In contrast, there are few complications that accompany cell surface antigen selection. The genes for the Leu-1 cell surface antigen, the IL-2 receptor, the low-affinity nerve growth factor receptor, and MDR1 have all been used for this purpose (27, 28, 30, 34 (33) . These bicistronic MDR1 vectors have been reported to have a titer of 1.2 x 104 CFU/ml (35) . This contrasts with our high-titer bicistronic vectors containing the human small cell CD24 cDNA.
Whether the vector system described here can be used to transduce HSCs and select the transduced cells prior to autologous transplantation into Gaucher patients remains to be determined. CD24 is expressed on the surface of most human B cells, which triggers the respiratory burst in mature granulocytes (36) , but its function and expression levels on human HSCs are not known in detail. It is therefore not clear whether overexpression of CD24 will have harmful effects on stem cell function or on the function of more differentiated hematopoietic cells. In vitro differentiation of sorted CD24-expressing progenitors generated normal hematopoietic colonies in vitro, but it is not clear whether proliferation and differentiation of human HSCs expressing CD24 will be normal in vivo. It is encouraging that high levels of sustained CD24 expression in multilineage hematopoietic cells after retroviral gene transfer did not cause any abnormalities of hematopoiesis in the recipient mice transplanted with CD24-expressing bone marrow for 4 months (29) . However, overexpression of the mouse homolog of CD24, heat stable antigen (HSA), has been reported to cause biological abnormalities in thymuses and T-cell development in transgenic mice (46) . It is not clear whether these differences between the consequences of HSA and CD24 expression in the mouse are due to higher expression levels of the HSA in the thymus or to the fact that human CD24 may not be functional in the mouse. Therefore, this bicistronic vector system might be very useful for gene therapy of Gaucher disease, provided that CD24 expression on hematopoietic cells will not be harmful in vivo.
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